Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I, Bray F. Cancer fact sheets: lung cancer. 2016th ed. Lyon: International Agency for Research on Cancer; 2016.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
Huang T, Chen X, Hong Q, Deng Z, Ma H, Xin Y, Fang Y, Ye H, Wang R, Zhang C, et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep. 2015;5:8897.
Wells AJ. Lung cancer from passive smoking at work. Am J Public Health. 1998;88:1025–9.
Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001;31:139–48.
Boffetta P. Involuntary smoking and lung cancer. Scand J Work Environ Health. 2002;28(Suppl 2):30–40.
Armadans-Gil L, Vaque-Rafart J, Rossello J, Olona M, Alseda M. Cigarette smoking and male lung cancer risk with special regard to type of tobacco. Int J Epidemiol. 1999;28:614–9.
Gajalakshmi V, Hung RJ, Mathew A, Varghese C, Brennan P, Boffetta P. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in southern India. Int J Cancer. 2003;107:441–7.
Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C, Tsugane S. Tobacco smoking and lung cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006;36:309–24.
Obtel M, Nejjari C, Tachfouti N, Abda N, Belakhel L, Mathoulin-Pelissier S. Estimating attributable fraction of lung cancer linked to smoking in Morocco. East Mediterr Health J. 2016;21:871–7.
Parkin DM. 2. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer. 2011;105(Suppl 2):S6–13.
Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF Jr. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001;1471:C1–10.
Wain LV, Shrine N, Miller S, Jackson VE, Ntalla I, Soler Artigas M, Billington CK, Kheirallah AK, Allen R, Cook JP, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med. 2015;3:769–81.
Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet. 2010;42:45–52.
Wilk JB, Shrine NR, Loehr LR, Zhao JH, Manichaikul A, Lopez LM, Smith AV, Heckbert SR, Smolonska J, Tang W, et al. Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med. 2012;186:622–32.
Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616–22.
Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–7.
Bierut LJ. Nicotine dependence and genetic variation in the nicotinic receptors. Drug Alcohol Depend. 2009;104(Suppl 1):S64–9.
Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, Duan W, Fox L, Grucza RA, Kern J, et al. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet. 2009;18:3125–35.
Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL, Thun MJ, Goate A, Calle EE. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev. 2008;17:3517–25.
Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG, Tiirikainen M, Wang H. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res. 2008;68:9137–40.
Spitz MR, Amos CI, Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 2008;100:1552–6.
Palestinian Central Bureau of Statistics (PCBS). The situation of Smoking practice in the Palestinian Territory on the occasion of the “Word No Tobacco Day”. http://www.pcbs.gov.ps/Portals/_pcbs/PressRelease/Fight_smok52011E.pdf. Accessed 23 Mar 2018.
PHIC. Health annual report. Gaza: Palestinian Ministry of Health; 2014.
Wangkumhang P, Chaichoompu K, Ngamphiw C, Ruangrit U, Chanprasert J, Assawamakin A, Tongsima S. WASP: a web-based allele-specific PCR assay designing tool for detecting SNPs and mutations. BMC Genom. 2007;8:275.
Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 1995;7:9.8.1–12. https://doi.org/10.1002/0471142905.hg0908s07.
Ensembl. Ensembl release 86. 2016th ed. Cambridge: WTSI/EMBL-EBI; 2016.
Shiraishi K, Kohno T, Kunitoh H, Watanabe S, Goto K, Nishiwaki Y, Shimada Y, Hirose H, Saito I, Kuchiba A, et al. Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis. 2009;30:65–70.
Xu ZW, Wang GN, Dong ZZ, Li TH, Cao C, Jin YH. CHRNA5 rs16969968 polymorphism association with risk of lung cancer-evidence from 17,962 lung cancer cases and 77,216 control subjects. Asian Pac J Cancer Prev. 2015;16:6685–90.
Ji X, Gui J, Han Y, Brennan P, Li Y, McKay J, Caporaso NE, Bertazzi PA, Landi MT, Amos CI. The role of haplotype in 15q25.1 locus in lung cancer risk: results of scanning chromosome 15. Carcinogenesis. 2015;36:1275–83.
Sun H, Pan Y, He B, Deng Q, Ying H, Chen J, Liu X, Wang S. Different effects of the three polymorphisms on 15q25.1 onlung cancer risk: evidence from published literatures. J Cancer Res Ther. 2016;12:12–9.
Zhan P, Song Y. CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis. Transl Lung Cancer Res. 2015;4:104–8.
Gu M, Dong X, Zhang X, Wang X, Qi Y, Yu J, Niu W. Strong association between two polymorphisms on 15q25.1 and lung cancer risk: a meta-analysis. PLoS ONE. 2012;7:e37970.
Hu B, Huang Y, Yu RH, Mao HJ, Guan C, Zhao J. Quantitative assessment of the influence of common variations (rs8034191 and rs1051730) at 15q25 and lung cancer risk. Tumour Biol. 2014;35:2777–85.
Ren JH, Jin M, He WS, Liu CW, Jiang S, Chen WH, Yang KY, Wu G, Zhang T. Association between CHRNA3 rs1051730 genotype and lung cancer risk in Chinese Han population: a case-control study. J Huazhong Univ Sci Technolog Med Sci. 2013;33:897–901.
VanderWeele TJ, Asomaning K, Tchetgen Tchetgen EJ, Han Y, Spitz MR, Shete S, Wu X, Gaborieau V, Wang Y, McLaughlin J, et al. Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol. 2012;175:1013–20.
He P, Yang XX, He XQ, Chen J, Li FX, Gu X, Jiang JH, Liang HY, Yao GY, He JX. CHRNA3 polymorphism modifies lung adenocarcinoma risk in the Chinese Han population. Int J Mol Sci. 2014;15:5446–57.
Wiencke JK, Thurston SW, Kelsey KT, Varkonyi A, Wain JC, Mark EJ, Christiani DC. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst. 1999;91:614–9.
Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res. 2003;63:6556–62.
Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer. 2005;92:426–9.
Wojas-Krawczyk K, Krawczyk P, Biernacka B, Grzybek M, Kolodziej P, Kucharczyk T, Mlak R, Milanowski J. The polymorphism of the CHRNA5 gene and the strength of nicotine addiction in lung cancer and COPD patients. Eur J Cancer Prev. 2012;21:111–7.
Wium-Andersen MK, Orsted DD, Nordestgaard BG. Tobacco smoking is causally associated with antipsychotic medication use and schizophrenia, but not with antidepressant medication use or depression. Int J Epidemiol. 2015;44:566–77.
Rode L, Bojesen SE, Weischer M, Nordestgaard BG. High tobacco consumption is causally associated with increased all-cause mortality in a general population sample of 55,568 individuals, but not with short telomeres: a Mendelian randomization study. Int J Epidemiol. 2014;43:1473–83.
Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, Totoki Y, Fujimoto A, Nakagawa H, Shibata T, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354:618–22.
Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer. 2009;124:36–45.
Zou W, Zou Y, Zhao Z, Li B, Ran P. Nicotine-induced epithelial-mesenchymal transition via Wnt/beta-catenin signaling in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2013;304:L199–209.
Vu T, Jin L, Datta PK. Effect of Cigarette Smoking on Epithelial to Mesenchymal Transition (EMT) in Lung Cancer. J Clin Med. 2016;5:44.
Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest. 2006;116:2208–17.
Olfson E, Saccone NL, Johnson EO, Chen LS, Culverhouse R, Doheny K, Foltz SM, Fox L, Gogarten SM, Hartz S, et al. Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans. Mol Psychiatry. 2016;21:601–7.
Chen LS, Baker T, Hung RJ, Horton A, Culverhouse R, Hartz S, Saccone N, Cheng I, Deng B, Han Y, et al. Genetic risk can be decreased: quitting smoking decreases and delays lung cancer for smokers with high and low CHRNA5 risk genotypes—a meta-analysis. EBioMedicine. 2016;11:219–26.
Munafo MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, Johnstone EC, Relton C, Johnson PC, Walther D, et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst. 2012;104:740–8.
Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P, Hashibe M, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17,000 individuals. Int J Epidemiol. 2010;39:563–77.
Tseng TS, Park JY, Zabaleta J, Moody-Thomas S, Sothern MS, Chen T, Evans DE, Lin HY. Role of nicotine dependence on the relationship between variants in the nicotinic receptor genes and risk of lung adenocarcinoma. PLoS ONE. 2014;9:e107268.
Hallden S, Sjogren M, Hedblad B, Engstrom G, Hamrefors V, Manjer J, Melander O. Gene variance in the nicotinic receptor cluster (CHRNA5-CHRNA3-CHRNB4) predicts death from cardiopulmonary disease and cancer in smokers. J Intern Med. 2016;279:388–98.
Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, et al. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis—a meta-analysis. JNCI J Natl Cancer Inst. 2015;107(5):djv100. https://doi.org/10.1093/jnci/djv100.
WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.